Angaben zu Autoren und Sponsoren finden Sie am Ende des Beitrags.

Logo GlaxoSmithKline GmbH & Co. KG
Quelle: © GlaxoSmithKline GmbH & Co. KG

GlaxoSmithKline GmbH & Co. KG.

Kontakt:
Prinzregentenplatz 9
81675 München
www.glaxosmithkline.de

Ausgewählte Pressemitteilungen:

Logo GSK
Quelle © GSK

04.06.20 - GSK announces new data presentations from the DREAMM program exploring investigational belantamab mafodotin in patients with relapsed/ refractory multiple myeloma

Pressemitteilung der GlaxoSmithKlince plc
GlaxoSmithKline (GSK) plc today announced new data from its DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical trial programme of belantamab mafodotin in relapsed/refractory multiple myeloma will be presented at the upcoming virtual edition of the 25th European Hematology Association (EHA) Annual Congress from 11-21 June 2020.

Weiterlesen

Logo GSK
Quelle © GSK

03.02.20 - GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma

Pressemitteilung der GlaxoSmithKlince plc
GSK today announced that the European Medicines Agency (EMA) validated the marketing authorisation application (MAA) for belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma. Belantamab mafodotin was accepted for accelerated assessment by the EMA’s Committee for Human Medicinal Products (CHMP).

Weiterlesen

Zuletzt aufgerufen am: 05.03.2021 14:05